Magle Group secures SEK 60M loan facility to bridge restructuring
What's the deal? Magle Group, the Swedish life sciences company listed on Nasdaq, has entered into a loan facility agreement of up to SEK 60M ($5.7M) with a group of its existing bondholders. The facility starts with an initial draw of SEK 25M, with the option to pull down an additional SEK 35M. The loan is meant to keep the company afloat while it works through a restructuring process.
The borrower is Magle ChemoswedDealroom has a profile for this one. Try Dealroom → AB, the company's wholly owned subsidiary. The loan carries interest at 3-month STIBOR plus 5.25% per annum, payable quarterly, and matures one year from the agreement date.
As security, both the parent company and the borrower have pledged first-ranking security over rights under certain royalty agreements. As a sweetener for lenders, Magle Group will issue bonus bonds equal to 5% of the utilised loan amount — SEK 1.25M on the initial draw — which can later convert into common shares.
Why now? The company needs near-term liquidity to bridge its ongoing restructuring. In April, Magle Group secured bondholder approval to waive maintenance tests on its SEK 350M senior secured bond until the end of 2026 — but that came with a condition: it must raise at least SEK 100M in net proceeds by June 30, 2026. The new facility buys the company time to meet that deadline and keep operations running.
What could go wrong? The loan still requires a further written procedure to get bondholder consent for key elements, including security-sharing arrangements and the issuance of bonus bonds. If that approval doesn't come through, the facility's structure could unravel.
There's also dilution risk. The planned directed share issue to convert bonus bonds into equity will need approval at an extraordinary general meeting within 180 days. Existing shareholders could see their stakes shrink.
And the fundamental question remains: can Magle Group's restructuring succeed? The company is already operating under waived financial covenants, and stacking new debt on top of SEK 350M in outstanding bonds raises the stakes considerably.
The signal: Magle Chemoswed is classified as a mature-stage companyDealroom has a profile for this one. Try Dealroom → on Dealroom, yet it finds itself relying on existing bondholders for emergency bridge financing — a sign that even established life sciences firms are struggling to access fresh capital in the current market. The bondholders' willingness to extend new credit, secured against royalty agreements rather than hard assets, suggests they see more recovery value in keeping the restructuring alive than in forcing a default on SEK 350M in outstanding bonds.
Read more: view.news.eu.nasdaq.com
